Zai Lab
Lanna C. has a diverse work experience spanning over a decade. Lanna started their career at SHJNJ as a Project Manager from October 2007 to May 2010. Following that, they worked at Sanofi as a Scientific Attache from June 2010 to 2012. Lanna then joined the company Ruo Shi as a Global Study Manager from July 2012 to 2014. After that, they moved to Novartis Institutes for BioMedical Research (NIBR) and held the position of Clinical Scientist from July 2014 to 2017. Currently, Lanna C. is the Executive Director of Clinical Operations at Zai Yin Medicine, starting in November 2017.
Lanna C. completed their high school education at the High School Affiliated to Nanjing Normal University from 1997 to 2003. Lanna then pursued a Bachelor's degree in Pharmaceutical Engineering at China Pharmaceutical University from 2003 to 2007. In 2012, they attended Fudan University for an unspecified degree in Public Health, which is still ongoing.
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.